Bioventus Inc., a leader in active healing innovations, announced a major achievement on July 30, 2025, with the U.S. Food and Drug Administration (FDA) granting 510(k) clearances for its two next-generation Peripheral Nerve Stimulation $(PNS.UK)$ products, TalisMann™ and StimTrial™. These approvals mark a significant milestone for Bioventus, expanding its innovative PNS solutions aimed at chronic pain management. The company plans a limited commercial release in selected U.S. markets during the third quarter, with a broader rollout anticipated in early 2026. This development reinforces Bioventus' commitment to delivering non-opioid, minimally invasive therapies, presenting a substantial growth opportunity in a PNS market projected to exceed $500 million by 2029.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。